Anixa Biosciences Inc
ANIX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANIX
Anixa Biosciences Inc is a clinical-stage biotechnology company developing cancer vaccines and CAR-T therapeutics, with no revenue to date and a reliance on licensing to large pharmaceutical companies for future profitability.
Key risk: No revenue generation
BioSniper Score
Based on 6 of 6 signals
Market Cap
$118.4M
Cash Runway
23.1 moLead Asset
lira-cel (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Apr 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst for Anixa Biosciences Inc.
Anixa Biosciences Inc is a clinical-stage biotechnology company developing cancer vaccines and CAR-T therapeutics, with no revenue to date and a reliance on licensing to large pharmaceutical companies for future profitability.
- Anixa has not generated any revenue from its therapeutics or vaccine programs as of April 30, 2026 [sec_mda · as of 2026-06-10].
- Cash, cash equivalents and short-term investments were approximately $13,686,000 at April 30, 2026, down from $15,174,000 at October 31, 2025 [sec_mda · as of 2026-06-10].
- The company expects its existing cash to fund operations for significantly longer than 12 months from June 10, 2026 [sec_mda · as of 2026-06-10].
- Research and development expenses for the three months ended April 30, 2025 were approximately $898,000 for cancer vaccines and $424,000 for CAR-T therapeutics [sec_mda · as of 2025-05-28].
- Anixa plans to achieve profitability by licensing its technologies to large pharmaceutical companies, which may take several years and depends on positive clinical trial results [sec_mda · as of 2026-06-10].
What works
- The company has sufficient cash to operate for significantly longer than 12 months from the date of its June 2026 report, reducing near-term financing risk [sec_mda · as of 2026-06-10].
- Anixa collaborates with third parties to develop its technologies, a business model that conserves funds [sec_mda · as of 2026-06-10].
- The company has two active programs—cancer vaccines and CAR-T therapeutics—providing multiple shots on goal [sec_mda · as of 2025-05-28].
What to weigh
- Anixa has never generated revenue from its therapeutics or vaccine programs and does not expect to in the near term [sec_mda · as of 2026-06-10].
- The company's path to profitability depends on licensing to large pharmaceutical companies, which may take several years or may not occur at all [sec_mda · as of 2026-06-10].
- Cash reserves declined by approximately $1,488,000 in the three months ended April 30, 2026, indicating a burn rate that could pressure runway if timelines extend [sec_mda · as of 2026-06-10].
From the filings
Quoted directly from source documents.
No revenue from therapeutics or vaccines
“We have not generated any revenue to date from our therapeutics or vaccine programs.”
SEC MD&A · June 10, 2026
Cash position and runway
“The Company had approximately $13,686,000 of cash, cash equivalents and short-term investments at April 30, 2026”
SEC MD&A · June 10, 2026
Business model relies on licensing
“We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies”
SEC MD&A · June 10, 2026
R&D spending on vaccines and CAR-T
“research and development expenses related to the development of our cancer vaccines and CAR-T therapeutics consisted of approximately $898,000 and $424,000, respectively.”
SEC MD&A · May 28, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · breast cancer vaccine — Phase 2 Readout: breast cancer vaccine — Topline results from the Phase 2 trial of the breast cancer vaccine will be a key efficacy and safety readout for the program.
Risks & what to watch (3)›
Key risks
- No revenue generation — Anixa has no revenue from its core programs and does not expect near-term revenue [sec_mda · as of 2026-06-10].
- Licensing-dependent profitability — Profitability hinges on licensing to large pharma, which may take years or fail [sec_mda · as of 2026-06-10].
- Cash burn rate — Cash declined ~$1.5M in three months; sustained burn could shorten runway [sec_mda · as of 2026-06-10].
What to watch
- Phase 2 topline data for the breast cancer vaccine expected by December 31, 2026 [catalyst].
- Cash burn rate and any future financing needs as the company advances clinical programs [sec_mda · as of 2026-06-10].
- Progress in CAR-T therapeutic development and any partnership or licensing announcements [sec_mda · as of 2025-05-28].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Anixa Biosciences Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Anixa Biosciences Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
23.1 months
D/E 0.11 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~123d
10 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
61
Total value held
$13.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,629,964 | $6.8M |
| d.a. davidson & co. | 539,272 | $1.4M |
| geode capital management, llc | 364,731 | $941K |
| vanguard fiduciary trust co | 191,074 | $493K |
| marshall wace, llp | 173,179 | $447K |
| blackrock, inc. | 170,103 | $439K |
| state street corp | 159,040 | $410K |
| susquehanna international group, llp | 133,668 | $345K |
| lpl financial llc | 80,976 | $209K |
| northern trust corp | 66,825 | $172K |
Showing top 10 of 61 institutional holders of Anixa Biosciences Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 3.6%
- Days to cover
- 11.7
- Shares short
- 1,149,762
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Anixa Biosciences Inc?
Anixa Biosciences Inc is a clinical-stage biotechnology company developing cancer vaccines and CAR-T therapeutics, with no revenue to date and a reliance on licensing to large pharmaceutical companies for future profitability.
What is Anixa Biosciences Inc's lead drug candidate?
Anixa Biosciences Inc's most advanced tracked candidate is lira-cel (Phase 1) for Initially focused on treating ovarian cancer (recurrent epithelial ovarian cancer).
What is Anixa Biosciences Inc's next catalyst?
Anixa Biosciences Inc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: breast cancer vaccine" — expected December 31, 2026.
Who is the CEO of Anixa Biosciences Inc?
Dr. Amit Kumar Ph.D. is the chief executive officer of Anixa Biosciences Inc (ANIX).
Where is Anixa Biosciences Inc headquartered?
Anixa Biosciences Inc (ANIX) is headquartered in San Jose, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.